Summary
The Sorafenib HCC Assessment Randomized Protocol [SHARP] trial demonstrated that treatment with sorafenib prolonged overall survival by 44% and prolonged time to progression by 73% for patients with advanced hepatocellular carcinoma.
- Gastrointestinal Cancers Clinical Trials
- © 2007 MD Conference Express